this is the default page template

The Centers for Medicare and Medicaid Services (CMS) released a proposed rule to mediate its 2018 decision to decrease Medicare Part B payments for 340B drugs. While the remedy is appreciated, the implementation is controversial as it implements a lengthy multi-year claw-back to achieve budget neutrality. Why is the remedy needed? How will the remedy work? What’s the catch?